MSLN and ovarian carcinoma: Another antibody–drug conjugate in a clinical trial currently underway for patients with advanced solid tumors including ovarian cancer, uses a mAb targeting MSLN conjugated to a cytotoxic drug BMS-986148 with and without Nivolumab (NCT02341625) [381].